Alliance Global Partners analyst Scott Henry lowered the firm’s price target on RenovoRx to $3.50 from $4 and keeps a Buy rating on the shares. The firm cites greater dilution from the equity offering than it had modeled for the target drop. RenovoRx’s cash runway has been extended into 2026 and the second interim analysis for TIGeR-PaC is targeted for late 2024/early 2025, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx Secures $11.1M Through Equity and Warrants Offering
- RenovoRx to present initial interim analysis of Phase III TIGeR-PaC trial
- RNXT Earnings this Week: How Will it Perform?
- RenovoRx promotes Leesa Gentry to chief clinical officer
- RenovoRx Struggles to Avoid Nasdaq Delisting Amid Leadership Changes
